Stockholders' Equity (Details) - USD ($) |
3 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
Mar. 31, 2023 |
Mar. 31, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Stockholders' Equity (Details) [Line Items] | |||||
| Authorized to issue and sale of stock | 17,000,000 | 17,000,000 | 700,000 | ||
| Common stock, shares authorized | 12,000,000 | 12,000,000 | |||
| Common stock, par value (in Dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 | ||
| Preferred stock, shares authorized | 5,000,000 | 5,000,000 | 5,000,000 | ||
| Preferred stock, par value (in Dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 | ||
| Preferred stock, shares outstanding | |||||
| Amount of ATM availability. (in Dollars) | $ 200,000 | $ 200,000 | $ 2,900,000 | ||
| Incurred professional fees (in Dollars) | $ 21,300 | ||||
| Exercisable term | 5 years | ||||
| Exercise price per share (in Dollars per share) | $ 21.6 | ||||
| Shares of common stock purchase | 21,600 | 51,000 | |||
| Options to purchase common stock | 64,900 | ||||
| Stock options term | 10 years | ||||
| Awardee over a period | 4 years | ||||
| Warrants to purchase common stock expired and cancelled | 67,900 | ||||
| Description of granted stock options | the Company granted stock options to employees to purchase 0.2 million shares of the Company’s common stock, including certain time and performance-based inducement awards, with grant date prices that ranged between $10.20 to $41.40 per share. The stock options have terms of ten years and are subject to vesting based on continuous service of the awardee over periods ranging from three to four years. The stock options have an aggregate grant date fair value of $5.8 million. | ||||
| Description of pursuant agreement | Pursuant to such agreement, the Company granted Dr. Sarret (1) a time-based inducement nonqualified stock option and (2) a performance-based inducement nonqualified stock option to purchase approximately 0.1 million shares of common stock. The options have an exercise price of $40.50 and the time-based grant will vest as to 25% of the shares on the one-year anniversary of the grant date, May 3, 2021, with the remaining shares subject to the option vesting in 36 equal monthly installments. The time-based inducement award has an aggregate grant date fair value of $2.2 million. As of December 31, 2021, Dr. Sarret satisfied a portion of the performance conditions and 21.6 thousand shares of the 43.3 thousand shares possible under the performance-based award vested. The performance-based award had a fair value of $0.1 million. | ||||
| Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased | 100,000 | ||||
| Warrants purchase | 900 | ||||
| Closing market price percentage | 85.00% | 85.00% | |||
| Issued shares of under ESPP | 5,600 | 589 | |||
| Employee compensation deferrals (in Dollars) | $ 25,000 | $ 16,800 | |||
| Future issuance of shares under ESPP | 10,500 | 10,500 | |||
| ATM program expires description | The Company’s ATM program expires in September 2023. | ||||
| At-the-Market Offering [Member] | |||||
| Stockholders' Equity (Details) [Line Items] | |||||
| Authorized to issue and sale of stock | 23,400 | 23,400 | 55,300 | ||
| Amount of ATM availability. (in Dollars) | $ 5,000,000 | $ 5,000,000 | |||
| Underwritten Public Offerings [Member] | |||||
| Stockholders' Equity (Details) [Line Items] | |||||
| Authorized to issue and sale of stock | 700,000 | ||||
| Incurred professional fees (in Dollars) | $ 1,200,000 | ||||
| Net of commissions (in Dollars) | $ 13,800,000 | ||||
| Warrant [Member] | |||||
| Stockholders' Equity (Details) [Line Items] | |||||
| Authorized to issue and sale of stock | 1,700 | ||||
| Shares of common stock purchase | 48,400 | ||||
| Warrants to purchase common stock expired and cancelled | 106,000 | ||||
| Cash proceeds (in Dollars) | $ 2,100,000 | ||||
| Warrants purchase | 9,600 | ||||
| Purchase of warrants | 2,000 | ||||
| Common stock exercise price (in Dollars per share) | $ 41.4 | ||||
| Vesting period, description | 1.7 thousand of these warrants were valued using the Black-Scholes option pricing model and the corresponding expense will be recognized over the service period of three years. 0.3 thousand of these warrants were performance based. During the year ended December 31, 2021, the performance criteria were met and the warrants were valued and expensed at the time the performance conditions were met. The warrants have terms that range from two to three years with vesting over a one-year period. | ||||
| Stock Option [Member] | |||||
| Stockholders' Equity (Details) [Line Items] | |||||
| Shares of common stock purchase | 42,100 | 500,000 | |||
| Options to purchase common stock | 19,400 | ||||
| Weighted average exercise price granted (in Dollars per share) | $ 10.42 | ||||
| Aggregate grant fair value (in Dollars) | $ 200,000 | ||||
| Cash proceeds (in Dollars) | $ 1,200,000 | ||||
| Stock Option [Member] | 2011 Plan [Member] | |||||
| Stockholders' Equity (Details) [Line Items] | |||||
| Remaining options to be issued | 200,000 | 200,000 | |||